Compare Nano Dimension Ltd - ADR (NNDM) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nano Dimension Ltd - ADR vs Novo Nordisk A/S — how do they compare? Nano Dimension Ltd - ADR trades at $1.51 (market cap $327.47M), while Novo Nordisk A/S trades at $44.91 (market cap $200.69B). The key difference: Novo Nordisk A/S is far larger — about 612.9× Nano Dimension Ltd - ADR's market cap, and Novo Nordisk A/S pays a 3.98% dividend while Nano Dimension Ltd - ADR pays none. Which is the better fit depends on your goals.
| NNDM | NVO | |
|---|---|---|
Market Cap | $327.47M | $200.69B |
Sector | Technology | Health |
52-Week High | $2.14 | $63.98 |
52-Week Low | $1.21 | $35.29 |
Enterprise Value | -$77.38M | $215.49B |
Dividend Yield | — | 3.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NNDM trades at $1.555, down 4.01% on the day, amid a bearish technical signal and negative cash flow. The company reported a net loss of $293.30M on $102.44M revenue in 2025, with a negative net income margin of 135.18%. Recent news highlights board changes, cost-saving initiatives, and a planned sale of MarkForged to Stratasys, aimed at reducing cash burn.
The outlook remains challenged by persistent losses and cash burn, though strategic divestitures may improve liquidity. Key risks include execution of turnaround plans and competitive pressures. Analyst sentiment is cautious given the financial performance and ongoing corporate restructuring.
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
